MiR-127 and BCL6 modulate the proliferation of breast cancer cell lines.

<p>(A) qRT-PCR analysis of miR-127 expression in WI-38, IMR-90, MCF7, and MDA-MB-231. U6 RNA was used for normalization. Data are presented as the mean ± SD from three independent experiments. (B) Western blot analysis of BCL6 in human fibroblasts, WI-38 and IMR-90, and the breast cancer cell lines MCF7 and MDA-MB-231. β-actin was used for normalization. (C) Growth curves of MCF7 and MDA-MB-231 cells transiently transfected with miR-127 mimic or negative control. Growth curves were generated by cell number at indicated times. Data are presented as the mean ± SD from three independent experiments. (D) Western blot analysis of BCL6, cyclin D1 and Phospho-Rb (Ser780) in MCF7 and MDA-MB-231 cells transiently transfected with the 50 nM miR-127-3p mimic or negative control. β-actin was used for normalization. (E) Cell cycle analysis was performed at 48 h after transfection.The histogram displays the percentage changes of G₀/G₁ and G₂/M when MCF7 cells transfected with miR-127 mimics and negative control. M1 and M2 show the spike of G₀/G₁ and G₂/M, respectively. (F) Growth curves of MCF7 and MDA-MB-231 cells transiently transfected by 50 nM BCL6 siRNA or negative control. (G) Western blot analysis of BCL6, cyclin D1 and Phospho-Rb (Ser780) in MCF7 and MDA-MB-231 cells 72 hours after transfection with 50 nM BCL6 siRNA or negative control. β-actin was used for normalization.